KOL Insight Archives | Page 4 of 16 | Report Store

Datamonitor Healthcare Meningococcal and Pneumococcal Vaccines KOL Interview – UK

An interview with a UK key opinion leader (KOL) on meningococcal and pneumococcal vaccination coverage rates, vaccination rate trends in main risk groups, key marketed vaccines, pipeline approaches, and addressing unmet needs.

November 12, 2018

Find out more

Crohn’s Disease KOL Interview – UK

$599.00

This discussion with a UK-based key opinion leader (KOL) includes in-depth opinions on the approved agents and late-stage pipeline drugs in the Crohn’s disease market. In the discussion, the KOL opines in detail about the long-term use of biologics and combinations in Crohn’s disease. The impact of biosimilars and the importance of cost regarding the choice of agents in the treatment of Crohn’s disease are also discussed.

October 13, 2022

Find out more

ADPD Alzheimer’s Disease Pulse

$599.00

Overview We performed a 5-question survey of 25 neurologists in the US to gauge current familiarity with Alzheimer’s Disease (AD) biomarkers and drugs in clinical development for disease modification. Drugs covered include: BIIB037/BART (BIIB), Solanezumab (LLY), Pioglitazone (Takeda), BAN2401 (ESALY/BIIB), MK-8931 (MRK).

March 19, 2015

Find out more

2015 Post-AAIC KOL Interview

$599.00

Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

August 1, 2015

Find out more

Triple-Negative Breast Cancer KOL Interview – US

$599.00

A US-based key opinion leader providers insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for triple- negative breast cancer. Diagnostic testing, biomarker disease segmentation, and unmet needs are also discussed. Key pipeline assets highlighted include balixafortide, Keytruda, sacituzumab govitecan, trastuzumab deruxtecan, and veliparib.

October 3, 2019

Find out more

Diffuse Large B-Cell Lymphoma (DLBCL) KOL Interview – US

$599.00

A US-based key opinion leader (KOL) gives insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for DLBCL. Therapies discussed include Polivy, Monjuvi, Zynlonta, CD19-directed CAR-T therapy and CD20-directed bispecific antibodies.

April 21, 2022

Find out more

Schizophrenia and Bipolar Disorder KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, long-acting injectables, late-phase pipeline therapies, and unmet needs for schizophrenia and bipolar disorder. Key pipeline assets highlighted include Lybalvi (ALKS 3831), MIN-101, Nuplazid, Caplyta, BXCL501, and six-monthly paliperidone depot injection.

April 28, 2021

Find out more

Datamonitor Healthcare HIV KOL Interview – Germany

$599.00

A German key opinion leader (KOL) provides insights into the HIV treatment market, including a discussion on prescribing trends, key marketed therapies, impact of generic launches, and pipeline therapies.

January 25, 2019

Find out more

Datamonitor Healthcare Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines

$599.00

The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.

October 30, 2020

Find out more

Non-Small Cell Lung Cancer KOL Interview – NH, US

$1,099.00

Datamonitor Healthcare interviewed a US-based oncologist with clinical trial and commercial experience of PD-1/L1 inhibitors to gauge his views

August 30, 2018

Find out more

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

$599.00

In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients.

October 12, 2018

Find out more

Dermatology KOL Interview

$599.00

BioMedTracker – Dermatology KOL Interview In recent years, patients have become more comfortable with aesthetic dermatology procedures as they have become more widespread.

October 31, 2014

Find out more

Wet Age-Related Macular Degeneration (Wet AMD) KOL Interview – US #2

$599.00

A US-based KOL speaks on the current market trends and how cost, durability, and efficacy play a key role in prescribing decisions. The KOL also talks about newer therapies that might overthrow current market leaders, and the future of newer biologics in the market.

September 29, 2022

Find out more

Post-AASLD US KOL Interview

$599.00

Over 95% SVR for easy-to-treat patients, and it’s one pill a day for 8-12 weeks for most. In that context, the only way you can improve up on that is to improve care for all populations, not just for easy-to-treat but the difficult-to-treat: decompensated cirrhotics, the post-transplant, and HIV co-infected patients.

December 16, 2014

Find out more

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

$599.00

This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for anemia in chronic kidney disease (CKD). Key topics discussed include current treatments for anemia in CKD, with a focus on ESAs and IV iron, and the future of HIF stabilizers as a potential treatment for the disease.

June 30, 2020

Find out more